Genentech

Genentech, Inc.
Company type	Subsidiary
Traded as	Nasdaq: DNA
Industry	Biotechnology
Founded	1976
Founders	Robert A. Swanson and Herbert Boyer
Headquarters	South San Francisco, California, United States
Key people	Ashley Magargee; (interim CEO); Ed Harrington; Levi Garraway; Stephen Williams; Sean Johnston; Severin Schwan; (chairman of Genentech Board of Directors, CEO of Roche Group); Anna Batt; Aviv Regev;
Products	Avastin, Herceptin, Rituxan, Perjeta, Kadcyla, Gazyva, Tarceva, Ocrevus, Polivy, Tecentriq, Xofluza, Hemlibra, Venclexta, Esbriet, Cotellic, Alecensa, Zelboraf, Nutropin, Actemra, Lucentis, Xolair, Activase, Cathflo Activase, Xeloda, Boniva, TNKase, CellCept, Pegasys, Pulmozyme, Tamiflu, Valcyte, Anaprox, Cytovene, EC-Naprosyn, Erivedge, Fuzeon, Invirase, Klonopin, Kytril, Naprosyn, Rocephin, Roferon-A, Romazicon, Valium, Xenical, Zenapax
Revenue	$26.4 billion (2020)
Number of employees	13,539 (July 2021)
Parent	Roche
Website	gene.com
	Footnotes / references;

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It operates as an independent subsidiary of holding company Roche. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

As of July 2021, Genentech employed 13,539 people.